grant

Enhanced Genetic Targeting of Specific Neuronal Populations Using a Minipromoter and Splicing Hybrid Approach

Organization TUFTS UNIVERSITY BOSTONLocation BOSTON, UNITED STATESPosted 1 Jul 2024Deadline 30 Jun 2026
NIHUS FederalResearch GrantFY2024AAV deliveredAAV deliveryAAV-based deliveryAAV-based viral deliveryAAV-mediated deliveryAICDAAICDA proteinAID geneAID proteinAdeno-Associated VirusesAdeno-associated-virus-based deliveryAgeAlternate SplicingAlternative RNA SplicingAlternative SplicingAmmon HornAmygdalaAmygdaloid BodyAmygdaloid NucleusAmygdaloid structureAnimalsBasic ResearchBasic ScienceBrainBrain Nervous SystemBrain regionBreedingCDA2 proteinCaM KIICaM PK IICaM kinase IICaMKIICell BodyCellsCommunitiesConnector NeuronConsumptionCornu AmmonisCre driverDNA RecombinationDNA TherapyDataData SetDependoparvovirusDependovirusDevelopmentDiseaseDisorderEncephalonEnhancersEnzyme GeneEnzymesEventExonsExtravasationFluorescence Activated Cell Sorting FractionationFluorescence-Activated Cell SortingFluorescence-Activated Cell SortingsFoundationsFrame Shift MutationFrameshift MutationFutureGene ExpressionGene Transfer ClinicalGeneticGenetic EnhancementGenetic InterventionGenetic RecombinationGoalsHippocampusHybridsIn VitroIn vivo analysisIndividualInjectionsIntercalary NeuronIntercalated NeuronsInterneuronsInternuncial CellInternuncial NeuronInvestigatorsKnock-inLabelLeakageLengthLinkMapsMental disordersMental health disordersMethodsMiceMice MammalsMurineMusNerve CellsNerve UnitNervous SystemNervous System DiseasesNervous System DisorderNeural CellNeurocyteNeurologic Body SystemNeurologic DisordersNeurologic Organ SystemNeurological DisordersNeuronsNeurosciencesNon-Polyadenylated RNAOrganismParvalbuminsPatientsPatternPopulationPsychiatric DiseasePsychiatric DisorderPublic HealthPublishingR-Series Research ProjectsR01 MechanismR01 ProgramRNARNA Gene ProductsRNA SeqRNA SplicingRNA purificationRNA sequencingRNAseqReading Frame Shift MutationRecombinationReporterResearchResearch GrantsResearch PersonnelResearch Project GrantsResearch ProjectsResearchersRiboTagRibonucleic AcidSamplingSpecificitySpeedSpillageSplicingSystemTechnologyTestingThalamic structureThalamusTherapeutic InterventionTimeTransgenic AnimalsTransgenic OrganismsTranslationsVariantVariationViral PackagingViral VectorVirus PackagingsWorkactivation-induced cytidine deaminaseactivation-induced deaminaseadeno associated virus groupadeno-associated viral vector deliveryadeno-associated virus deliveryadeno-associated virus mediated deliveryadenovirus mediated deliveryagesamygdaloid nuclear complexcalcium-dependent CaM kinase IIcalmodulin-dependent protein kinase IIcell typecombinatorialconfocal imagingdelivered with AAVdelivery with AAVdesigndesigningdevelopmentalexcitatory neuronexperimentexperimental researchexperimental studyexperimentsgene repair therapygene therapygene-based therapygene-based treatmentgene-directed therapygene-targeted therapygene-targeted treatmentgenetic therapygenomic therapyhippocampalimprovedin vivo evaluationin vivo testinginhibitory neuroninnovateinnovationinnovativeintervention therapyknockinliving systemmachine learned algorithmmachine learning algorithmmachine learning based algorithmmental illnessminiaturizeminiaturizedneurological diseaseneuronalnovelpre-clinical researchpreclinical researchpromoterpromotorpsychiatric illnesspsychological disorderrecombinasescRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingthalamictooltranscriptome sequencingtranscriptomic sequencingtransgenictranslationvector
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY. Current AAV-based methods to target inhibitory interneurons, and their subpopulations,
remain too leaky to use with recombinases such as Cre. Furthermore, the specificity of the widely used CaMKII

minipromoter to access excitatory neurons also displays off-target expression. The long-term goal of this project

is to develop ultra-specific AAVs that can overcome leakage into non-target cells and therefore be compatible

with recombinase enzymes. The overall objective of this application is to develop and test hybrid AAVs that

harness alternative splicing, through splicing linked expression design (SLED), in combination with current state-

of-the-art minipromoters and enhancers. The central hypothesis is that this hybrid approach will increase target

specificity, enabling the delivery of recombinases like Cre. The rationale for the project is to generate and share

novel tools to speed up basic science research and reduce the reliance on knockin and transgenic Cre lines to

target distinct populations of neurons. Increasing the specificity of AAVs would also benefit future gene therapy

interventions, where highly controlled gene expression is essential. The central hypothesis will be tested by

pursuing two specific aims: 1) Design and rigorously evaluate the ability of miniaturized enhancer-SLED hybrid

constructs to deliver Cre with increased specificity; and 2) Generate sequencing datasets from subcortical brain

regions to uncover cell type-specific splicing events. Under the first aim, cell-specific exons for inhibitory

interneurons (INs), parvalbumin positive interneurons (PV-INs), and excitatory neurons (ENs) will be identified

and utilized to make hybrid SLED AAVs with existing minipromoters or enhancers. These AAVs will be screened

in vitro, then leading candidates will be thoroughly tested in vivo in mice to rigorously evaluate their specificity.

For the second aim, the RiboTag technology will be used to isolate bulk RNA samples from ENs and PV-INs from

the amygdala and thalamus, allowing high depth RNA sequencing to map patterns of cell and region-specific

alternative splicing. This will enable integration with published cortical and hippocampal datasets so that region-

specific alternative splicing patterns can be identified. This will further a basic scientific understanding of

alternative splicing and support the future development of SLED vectors targeting subcortical cell populations

relevant to psychiatric disease. The proposed research is innovative because it combines SLED with the leading

enhancer and minipromoter technologies to create hybrid AAV constructs predicted to achieve a level of

specificity beyond what is possible with each individual approach. This proof of principle experiment could open

new horizons for the subpopulations of cells that can be targeted genetically. Furthermore, this research project

will generate a valuable dataset tailored to comparing alternative splicing across cell types and brain regions.

This is necessary because single cell RNA sequencing experiments, while invaluable, rarely have the

sequencing depth needed to detect alternative splice variants. The tools and datasets generated and shared in

this project promise broad utility both within and beyond the field of neuroscience.

Grant Number: 1R21NS135454-01A1
NIH Institute/Center: NIH

Principal Investigator: Alexei Bygrave

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →